Introducing New Peptides for Cancer and Apoptosis Research

Tumor derived, tumor associated antigens (TAA) or homing peptides are used as targets for the development of cancer vaccines (such as NY-ESO-1 peptide vaccine) as they illicit an immune response against cells containing the cancer antigen. Owing to differential expression in various tissues, some of these peptides serve as biomarkers and can also play immuno-modulatory roles within the immune landscape of cancer pathways such as Mucin, Melan-A-MART, PD-L1 etc. More recently, tumor specific antigens or tumor specific neoantigens (TSNA) that arise from tumor cell mutations are being identified in a large number of cancer patients. These neoantigens, which are peptides, are processed and presented to the T cells in association with MHC molecules to elicit an immune response against the underlying cancer.
As conventional cancer treatments present challenges such as resistance, and lack of selectivity, newer alternatives are being explored to provide advancements towards better clinical outcomes. Peptides offer a high potential in cancer therapy, owing to high target specificity and selectivity, with low toxicity.

AnaSpec is a globally recognized biotechnology company that manufactures and sells quality catalog and custom R&D, GLP, and GMP proteomic related products and services to the biopharmaceutical industry, diagnostic companies, agro-food firms, academia, and governmental institutions. They have a a collection of 1000+ catalog peptides categorized across 11 research areas.
As a reliable distributor and channel partner of AnaSpec in India, BTL Biotechno Labs Pvt. Ltd. takes pride in announcing the launch of their nine new peptides which have the ability to trigger Apoptosis in cancer cells, which is the routine mechanism that eliminates unnecessary or damaged cells, essential for homeostasis in tissues, organs and the organism as a whole.

KT2 CAT#AS-65672; AAP-H CAT# AS-65677; CT20p CAT# AS-65673; LVTX-8 CAT# AS-65674; ps8-derived peptide 327, CAT#AS-65675; TAT-327, CAT#s-65676; F3 peptide, CAT#AS-65678; LS10, CAT#AS-65679; NG2 ligand peptide CAT# AS-65680

For more details, please follow the link below:
Here 

For more such updates follow us on LinkedIn